Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,KDMN,10526000.0,171974000,15274000,,-28378000,,-28378000,12596000,264000,-27403000,-27403000,-203000,-1229000,,,,0,360000,27763000,96000,-975000,,-28378000,-28921000,487230000.0,275903000.0,14106000.0,922000.0,335107000.0,171000.0,-473025000.0,278000.0,3580000.0,-270000.0,2126000.0,132018000.0,28255000.0,2718000.0,-270000.0,16396000.0,310705000.0,2300000.0,173949000.0,1519000.0,232891000.0,22000.0,12273000.0,-115194000,1299000,-115395000,232394000,200522000,-5178000,1128000,57595000,-27532000,337000,80000,-824000,-33000000,4974000,-201000,282450000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,5.43,1630526403,-0.05000019,5.5,5.5301,5.32,2608827,"Kadmon Holdings, Inc.",NMS,PRE,0.29436445,0,False,False,-0.9124123,5.32 - 5.5301,5.48,0.0,0.0,9,30,finmb_114935891,NasdaqGS,"Kadmon Holdings, Inc.",USD,3785689,3358200,2.2849998,0.72655004,3.145 - 5.73,-0.3000002,-0.052356053,3.145,5.73,1604610000,1604610000,1604610000,-0.649,-0.5,2,-0.74,-7.3378377,0.082,4.621714,0.8082857,0.17488873,4.195109,1.2348909,933818816,-10.86,66.219505,15,America/New_York,EDT,-14400000,1.55,,,5.73,3.14,4.62,4.2,3.79M,3.36M,171.97M,,134.64M,0.17%,99.57%,39.73M,25.51,24.42%,23.10%,40.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,936.59%",-27.46%,-109.10%,1.91M,0.01,-94.70%,6.29M,-112M,-110.14M,-0.65,,305.97M,1.78,254.38M,429.67,11.00,0.08,-95.25M,-58.36M,Value,10016,Healthcare,127,10,2,"Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.",New York,833 900 5366,NY,5,1609372800,1622505600,6,United States,http://www.kadmon.com,86400,7,450 East 29th Street,646 666 7978,Biotechnology
t-1,KDMN,67888000.0,171974000,18734000,,-28040000,,-27858000,12877000,772000,-31239000,-31239000,400000,-8000,,,,-182000,1015000,32254000,243000,3199000,,-27858000,-28402000,515429000.0,46687000.0,71468000.0,1082000.0,162710000.0,171000.0,-444104000.0,278000.0,3580000.0,-28000.0,2130000.0,74423000.0,29471000.0,1699000.0,-28000.0,17399000.0,137301000.0,2300000.0,59999000.0,1095000.0,1359000.0,102000.0,10933000.0,-5247000,-1029000,-5399000,232394000,273000,2237000,273000,-31526000,-26400000,-2258000,129000,-322000,-33000000,2701000,-152000,107830000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,5.43,1630526403,-0.05000019,5.5,5.5301,5.32,2608827,"Kadmon Holdings, Inc.",NMS,PRE,0.29436445,0,False,False,-0.9124123,5.32 - 5.5301,5.48,0.0,0.0,9,30,finmb_114935891,NasdaqGS,"Kadmon Holdings, Inc.",USD,3785689,3358200,2.2849998,0.72655004,3.145 - 5.73,-0.3000002,-0.052356053,3.145,5.73,1604610000,1604610000,1604610000,-0.649,-0.5,2,-0.74,-7.3378377,0.082,4.621714,0.8082857,0.17488873,4.195109,1.2348909,933818816,-10.86,66.219505,15,America/New_York,EDT,-14400000,1.55,,,5.73,3.14,4.62,4.2,3.79M,3.36M,171.97M,,134.64M,0.17%,99.57%,39.73M,25.51,24.42%,23.10%,40.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,936.59%",-27.46%,-109.10%,1.91M,0.01,-94.70%,6.29M,-112M,-110.14M,-0.65,,305.97M,1.78,254.38M,429.67,11.00,0.08,-95.25M,-58.36M,Value,10016,Healthcare,127,10,2,"Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.",New York,833 900 5366,NY,5,1609372800,1622505600,6,United States,http://www.kadmon.com,86400,7,450 East 29th Street,646 666 7978,Biotechnology
t-2,KDMN,93768000.0,171974000,17268000,,-24606000,,-24606000,10865000,28000,-28005000,-28005000,-100000,-8000,,,,0,390000,28395000,362000,3399000,,-24606000,-25149000,512904000.0,47630000.0,97348000.0,1016000.0,188989000.0,171000.0,-415702000.0,461000.0,3580000.0,-25000.0,2134000.0,105949000.0,28160000.0,679000.0,-25000.0,18633000.0,162342000.0,2300000.0,53752000.0,373000.0,2378000.0,28000.0,12110000.0,-40387000,406000,-40518000,-1000,279000,-160000,280000,-63854000,-23615000,1307000,-60000,23000,-33000000,-525000,-131000,134182000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,5.43,1630526403,-0.05000019,5.5,5.5301,5.32,2608827,"Kadmon Holdings, Inc.",NMS,PRE,0.29436445,0,False,False,-0.9124123,5.32 - 5.5301,5.48,0.0,0.0,9,30,finmb_114935891,NasdaqGS,"Kadmon Holdings, Inc.",USD,3785689,3358200,2.2849998,0.72655004,3.145 - 5.73,-0.3000002,-0.052356053,3.145,5.73,1604610000,1604610000,1604610000,-0.649,-0.5,2,-0.74,-7.3378377,0.082,4.621714,0.8082857,0.17488873,4.195109,1.2348909,933818816,-10.86,66.219505,15,America/New_York,EDT,-14400000,1.55,,,5.73,3.14,4.62,4.2,3.79M,3.36M,171.97M,,134.64M,0.17%,99.57%,39.73M,25.51,24.42%,23.10%,40.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,936.59%",-27.46%,-109.10%,1.91M,0.01,-94.70%,6.29M,-112M,-110.14M,-0.65,,305.97M,1.78,254.38M,429.67,11.00,0.08,-95.25M,-58.36M,Value,10016,Healthcare,127,10,2,"Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.",New York,833 900 5366,NY,5,1609372800,1622505600,6,United States,http://www.kadmon.com,86400,7,450 East 29th Street,646 666 7978,Biotechnology
t-3,KDMN,116209000.0,171974000,16516000,,-27152000,,-27152000,10068000,-536000,-26920000,-26920000,-200000,-5000,,,,0,248000,27168000,784000,-232000,,-27152000,-27670000,510171000.0,49987000.0,119789000.0,1618000.0,213244000.0,171000.0,-390553000.0,461000.0,3580000.0,,2139000.0,169803000.0,30138000.0,1359000.0,,19779000.0,185446000.0,2300000.0,12492000.0,396000.0,1699000.0,116000.0,11674000.0,15510000,4912000,15376000,3058000,52080000,-962000,49022000,49757000,-17699000,2276000,-238000,838000,-33000000,2727000,-134000,155308000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,5.43,1630526403,-0.05000019,5.5,5.5301,5.32,2608827,"Kadmon Holdings, Inc.",NMS,PRE,0.29436445,0,False,False,-0.9124123,5.32 - 5.5301,5.48,0.0,0.0,9,30,finmb_114935891,NasdaqGS,"Kadmon Holdings, Inc.",USD,3785689,3358200,2.2849998,0.72655004,3.145 - 5.73,-0.3000002,-0.052356053,3.145,5.73,1604610000,1604610000,1604610000,-0.649,-0.5,2,-0.74,-7.3378377,0.082,4.621714,0.8082857,0.17488873,4.195109,1.2348909,933818816,-10.86,66.219505,15,America/New_York,EDT,-14400000,1.55,,,5.73,3.14,4.62,4.2,3.79M,3.36M,171.97M,,134.64M,0.17%,99.57%,39.73M,25.51,24.42%,23.10%,40.54M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,936.59%",-27.46%,-109.10%,1.91M,0.01,-94.70%,6.29M,-112M,-110.14M,-0.65,,305.97M,1.78,254.38M,429.67,11.00,0.08,-95.25M,-58.36M,Value,10016,Healthcare,127,10,2,"Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.",New York,833 900 5366,NY,5,1609372800,1622505600,6,United States,http://www.kadmon.com,86400,7,450 East 29th Street,646 666 7978,Biotechnology
